Patterns of outcome measurement in Parkinson's disease clinical trials

Neuroepidemiology

Volumn 19, Issue 2, 2000, Pages 100-108

  Mitchell, Susan L ^a   Harper, Dan W ^b   Lau, Anita ^b   Bhalla, Rishi ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b NONE

Author keywords

Clinical trials; Endpoint; Measurement; Outcome; Parkinson's disease; Scales

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; SELEGILINE;

AGE; ARTICLE; COGNITION; DATA BASE; DRUG SCREENING; HEALTH STATUS; OUTCOMES RESEARCH; PARKINSON DISEASE;

EID: 0034001175     PISSN: 02515350     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026244     Document Type: Article

References (42)

1. Hoehn MM, Yahr MD: Parkinsonism: Onset, progression and mortality. Neurology 1967;17:427-442.
2. Fahn S, Elton RL, members of the UPDRS Development Committee: The Unified Parkinson's Disease Rating Scale; in Fahn S, Marsden CD, Calne DB, Goldstein M (eds): Recent Developments in Parkinson's Disease. Florham Park, Macmillan Healthcare Information, 1987, vol 2, pp 153-163, 293-304.
3. Steg G, Ingvarsson PE, Johnels B, Valls M, Thorselius M: Objective measurement of motor disability in Parkinson's disease. Acta Neurol Scand 1989;126:67-75.
4. Webster DD: Critical analysis of the disability in Parkinson's disease. Mod Treat 1968;5:257-258.
5. Duvoisin RC: The evaluation of extrapyramidal disease; in de Ajuriaguerra J, Gauthier G (eds): Monoamines noyaux gris centraux et syndrome de Parkinson. Paris, Masson, 1971.
6. Canter CJ, de la Torre R, Mier M: A method of evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis 1961;133:143-147.
7. Lieberman A, Dziatolowki M, Gopinathan G, et al: Evaluation of Parkinson's disease: in Goldstein M (ed): Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects. New York, Raven, 1980, pp 277-286.
8. Diamond SG, Markham CH, Treciokas LJ: A double-blind comparison of levodopa, madopar and sinemet in Parkinson's disease. Ann Neurol 1978;3:267-272.
9. Parkes JD, Zilka KJ, Calver DM, Knill-Jones RP: Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet 1970;i: 259-262.
10. Kurlan R, Rothfield KP, Woodward WR, et al: Erratic gastric emptying of levodopa may cause 'random' fluctuations of parkinsonian mobility. Neurology 1988;38:419-421.
11. Barbeau A, Duvoisin RC, Gerstenbrand F, Lakke JP, Marsden CD: Classification of extrapyramidal disease. J Neurol Sci 1981;51:311-327.
12. Schwab JF, England AC: Projection technique for evaluating surgery in Parkinson's disease; in Billingham FH, Donaldson MC (eds): Third Symposium on Parkinson's Disease. Edinburgh, Livingstone, 1969, pp 152-157.
13. Bergner M, Bobbitt RA, Canter WB, Gilson BS: The Sickness Impact Profile: Development and final revision of a health status measure. Med Care 1981;19:787-805.
14. Folstein MF, Folstein S, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
15. Tugwell P, Bombardier CA: A methodologic framework for developing and selecting endpoints in clinical trials. J Rheumatol 1982;9:758-762.
16. Boers M, Brooks P, Strand CV, Tugwell P: The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998;25:198-199.
17. Cranney A, Tugwell P, Cummings S, et al: Osteoporosis clinical trial endpoints: Candidate variables and clinimetric properties. J Rheumatol 1997;24:1222-1229.
18. McDowell I, Newell C (eds): Measuring Health, ed 2. New York, Oxford University Press, 1996, vol 7, pp 29-36.
19. Landis J, Koch G: The measurement of observer agreement for categorical data. Biometrics 1997;33: 671-679.
20. SAS Institute Inc: SAS/STAT User's Guide Version 6.12 for Windows. The Frequency, Univariate and Logist Procedures. Cary, Sas Institute, 1997.
21. EuroQol Group: EuroQol - A new facility for the measurement of health related quality of life. Health Policy 1990;12:199-208.
22. Hunt SM, McEwen J, McKenna S: Measuring health status: A new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985;35:185-188.
23. Martinez-Martin P, Gil-Nagel A, Morlair Garcia L, Balseirs Gomez J, Martinez-Sarries J, Bermejo F, the Cooperative Multicentric Group: Unified Parkinson's Disease Rating Scale characteristics and structure. Mov Disord 1994;9:76-83.
24. Louis ED, Lynch TL, Marder K, Fahn S: Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale. Mov Disord 1996;11: 185-192.
25. van Hilten JJ, van der Zwan AD, Zwinderman AH, Roos RAC: Rating impairment and disability in Parkinson's disease rating scale. Mov Disord 1994;9:84-88.
26. Jankovic J, McDermott M, Carter J, et al: Variable expression of Parkinson's disease: A base-line analysis of the DATATOP cohort. Neurology 1990;40:1529-1534.
27. Shoulson I, Fahn S, Brin M, et al: Correlates of clinical decline in early Parkinson's disease (abstract). Neurology 1987;37:278.
28. Stebbins G, Goetz C, Flourney T: Unified Parkinson's Disease Rating Scale: Reliability and factorial validity of the motor examination section (abstract). Ann Neurol 1991;30: 298.
29. Richards M, Marder K, Cote L, Mayeux R: Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord 1994;9:89-91.
30. Nouzeilles M, Merells M: Correlation between results of motor section of UPDRS and Webster Scale. Mov Disord 1997;12:613.
31. Gianneschi A, Degl'Innocenti F, Magnolfi S, et al: Evolution of Parkinson's disease: Reliability of three rating scales. Neuroepidemiology 1988;7:38-41.
32. Ginanneschi A, Degl'Innocenti F, Magnolfi S, et al: Evolution of Parkinson's disease: A new approach to disability. Neuroepidemiology 1991;10:282-287.
33. Geminiani G, Cesana B, Tamma F, et al: Interobserver reliability between neurologists in training of Parkinson's disease rating scales: A multicenter study. Mov Disord 1991;6:330-335.
34. Hely M, Chey T, Wilson A, et al: Reliability of the Columbia Scale for assessing signs of Parkinson's disease. Mov Disord 1993;8:466-472.
35. Montgomery G, Reynolds N, Warren R: Qualitative assessment of Parkinson's disease: Study of reliability and data reduction with an abbreviated Columbia Scale. Clin Neuropharmacol 1985;8:83-92.
36. Baas H, Stecker K, Fischer P: Value and appropriate use of rating scales and apparative measurements in quantification of disability in Parkinson's disease. J Neural Transm (Park Dis Dement Sect) 1993;5:45-61.
37. Junque C, Peiro A, Tordesillas C, Grau-Veciana J: Evolution of disability in Parkinson's disease: Clinical evaluation and instrumental tests. Funct Neurol 1987;2:293-300.
38. Henderson L, Kennard C, Crawford T, et al: Scales for rating motor impairment in Parkinson's disease: Studies of rehabilitative and convergent validity. J Neurol Neurosurg Psychiatry 1991;54:8-24.
39. Diamond S, Markham C: Evaluating the evaluations: Or how to weigh the scales of parkinsonian disability. Neurology 1983;33:1089-1099.
40. Lang AE: Clinical rating scales and videotape analysis: in Koller WC, Paulson G (eds): Therapy of Parkinson's Disease and Movement Disorders, ed 2. New York, Dekker, 1995, pp 21-46.
41. Martinez-Martin P: Rating scales in Parkinson's disease; in Jankovic J, Tolosa E (eds): Parkinson's Disease and Movement Disorders, ed 2. Baltimore, Williams and Wilkins, 1993, pp 281-292.
42. Rabey JM, Bass H, Bonuccelli U, Brooks D, et al: Evaluation of the short Parkinson's evaluation scale: A new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol 1997;20:322-337.